The PennZone

  • Home
  • Business
  • Health
  • Construction
  • Financial
  • Automotive
  • Technology
  • Arts
  • Sports

Actuated Medical Developing Technology to Improve Targeting for Next-Generation Alcohol Use Disorder Treatments
The PennZone/10278266

Trending...
  • Turbo vs. Experts: Tracking OddsTrader's AI Performance at the NFL's Midpoint
  • Emeritus Addresses Hospital Bed Shortages with Smart Storage Solutions
  • Outreaching.io Appoints Rameez Ghayas Usmani as CEO, Recognized as Best HARO Link Building Expert in the United States
Actuated Medical Inc.
BELLEFONTE, Pa. - PennZone -- Treating alcohol misuse remains a major challenge worldwide.  Given the diverse biological processes that contribute to alcohol use disorder, new medications are needed to provide a broader spectrum of treatment options. Some people may respond to a medication that helps with craving, others may respond to a medication that relieves impulsivity, others may respond to a medication that reverses the negative emotional state of withdrawal or protracted withdrawal. Just like any other medical condition, people with alcohol use disorder deserve to have a range of treatment options available to them. Scientists are working to develop a larger menu of pharmaceutical treatments that could be tailored to individual needs.

Actuated Medical's innovative NeuralGlider Injector will enable the delivery of next-generation medications into small targets deep in the brain, to fundamentally change the trajectory of alcohol use disorder and improve outcomes.  The goal is to deliver a therapeutic that will damp down cravings enough for other therapies to have a chance to work.  The therapeutic gets delivered accurately to the target and stays there.

Actuated Medical, Inc. has been awarded a $3 million pre-clinical Phase II Small Business Innovative Research (SBIR) grant from the National Institutes of Health-National Institute on Alcohol Abuse and Alcoholism to develop the "Oscillated Insertion Tool for Minimally Invasive, Low-Damage, Accurate Placement of Delivery Cannula to Improve Efficacy for DREADDS (designer receptors exclusively activated by designer drugs) Therapy in Alcohol Addiction Treatment" which will be commercially recognized as the NeuralGlider Injector.

More on The PennZone
  • Inframark Expands Its Specialized Automation and Intelligence Capabilities, Adds Dmytryka Jacobs Engineers
  • Sustainable Santa Returns to Old Sacramento
  • Upcoming Launch of Retail Crypto Cloud Mining Platform with Daily Rewards in a Transparent Revenue-Share Model: iMD Companies, Inc. Stock Symbol: ICBU
  • BumblebeeSmart Introduces Rounded Busy Board Set for Preschoolers
  • CRH Healthcare Opens 100th Urgent Care Clinic with Second Peachtree Immediate Care Location in Covington

"Many of us know someone who is dealing with an alcohol addiction and have felt helpless as we watched them suffer. That is why we are so excited to develop and commercialize our NeuralGlider Injector technology as it may one day help to offer a more effective treatment option for those afflicted with alcohol use disorder." Maureen L. Mulvihill, Ph.D., Actuated Medical President, CEO, & Co-Founder.

About Actuated Medical, Inc.

Actuated Medical is a Pennsylvania medical device product innovator founded in 2006 on the entrepreneurial idea that electronically controlled motion can solve clinical needs and improve patient outcomes. They are developing products in the areas of neuroscience, critical care, gastroenterology, and pediatrics. Their Actuated Neuroscience Division focuses on developing tools to assist researchers in understanding neurological conditions. Recently, they were awarded a 5-year Contract under the National Institutes of Health (NIH) Blueprint MedTech (BPMT) initiative to assist brain researchers conduct their FDA compliant testing. Actuated has 42 issued patents and 7 FDA 510(k) clearances. They have been the recipient of a 2014 & 2020 SBA Tibbets Awards for SBIR commercialization excellence. Actuated's CEO was the 2020 Life Sciences Pennsylvania CEO of the Year due to the teams Covid PPE pivot.

More on The PennZone
  • COHN Named Colorado State-Approved Vendor for Advertising & Marketing Services
  • The Kryder Law Group, LLC Report Reveals Commercial Air Travel Is Safer Than You Think
  • RTC Communications Preliminarily Awarded $3.1 Million Federal BEAD Grant to Expand Fiber Broadband in Southern Indiana
  • She's Been Ready for Weeks, He Starts in the Final 72 Hours – The Great Christmas Shopping Divide
  • Following a Global Sell-Out, The World's No.1 Superstar™ Unveils a Fashion Line Rebrand

More information about Actuated neural device innovations.

See www.actuatedneuroscience.com

NIH Disclaimer.

Research reported in this publication was supported by the National Institute On Alcohol Abuse And Alcoholism of the National Institutes of Health under Award Number R44AA030512. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.

###

For more information about this topic, please contact Maureen L. Mulvihill, Ph.D. by phone at 814-355-0003 or email at info@actuatedmedical.com.

Additional information can be found by visiting:

https://actuatedmedical.com

https://actuatedneuroscience.com

Contact
Actuated Medical
***@actuatedmedical.com


Source: Actuated Medical, Inc.

Show All News | Report Violation

0 Comments
1000 characters max.

Latest on The PennZone
  • Operational Agility in High Demand: FOCUS Expands to Serve a Changing Insurance Market
  • Bahamas Import Assistant Launches Same-Day Pet Permit Service Under BAHFSA's 2024 Expansion
  • Liftoff Enterprises Launches Liftoff Spotlight,™ A Nationally Broadcast Platform Turning Conversations Into Revenue
  • From November 24th to 27th, Fuqing Invites You to Join Us at BIG 5 to Jointly Build a New Future for Middle Eastern Architecture
  • Dispelling Holiday Suicide Myth: CDC Data Shows Suicide Rates Lowest in December; International Survivors of Suicide Day Emphasizes Need for Action
  • Stratum Nutrition's OVOLUX™ Named 2025 "Collagen Ingredient of the Year" by Beauty Innovation Awards
  • Sons of Liberty Museum Unveils "America at 250" Mobile Exhibit on Veterans Day 2025
  • Revenue Expansion, Regulatory Momentum, and a Leadership Position in the $750 Million Suicidal Depression: NRx Pharmaceuticals (N A S D A Q: NRXP)
  • Bent Danholm Releases New Video Breaking Down the Rising Debate Over 50-Year Mortgages
  • New Smile Now Introduces RAYFace 3D Scanner to Advance Digital Surgery
  • Ali Alijanian, DDS Featured in The Profitable Dentist Magazine
  • "Meet the Eatmons" Offer Financial Advice ahead of the Holidays
  • CCHR: Study Finds Involuntary Commitment Fails to Prevent Suicide, Raises Risk
  • Slotozilla's Q3 2025: SBC Lisbon Outcomes and Partnership Expansion
  • Historic Announcement for the Global Car Rental Industry
  • Siembra Brings 18 Latinx Artists Together in Brooklyn Exhibition
  • Gramercy Tech Launches StoryStream
  • Entrigue Magazine LLC Announces Strategic Media Partnership with Reewind Network LLC
  • Turbo vs. Experts: Tracking OddsTrader's AI Performance at the NFL's Midpoint
  • Outreaching.io Appoints Rameez Ghayas Usmani as CEO, Recognized as Best HARO Link Building Expert in the United States

Popular on PennZone

  • New Article by Roy J. Meidinger – Examines Hidden Hidden Healthcare Kickbacks - 459
  • Mensa Foundation's New Science Program Encourages Hands-On Discovery
  • GitKraken Launches Insights to Help Engineering Leaders Quantify AI Impact and Improve Developer Experience
  • Blogging Pioneer Sherry Bennett Celebrates 29 Years Online - From College Blogger to Successful Entrepreneur
  • J French's #1 Album "I Don't Believe in Bad Days" Enters the Grammy Conversation
  • Crypto Betting Odds 2025: Bookmakers Review Analyzes Market Predictions and Year-End Price Lines
  • 'Wild Hermit Wellness' Has Achieved Bestseller Status in Just 2 Months Since Launch Of Organic Skincare Line
  • Bookmakers Review Releases 2028 Democratic Nominee Betting Odds: Newsom Leads Early Field
  • The OpenSSL Corporation and the OpenSSL Foundation Celebrate the Success of the Inaugural OpenSSL Conference in Prague
  • Assent Recognizes Manufacturers for Leading Supply Chain Sustainability Programs

Similar on PennZone

  • Upcoming Launch of Retail Crypto Cloud Mining Platform with Daily Rewards in a Transparent Revenue-Share Model: iMD Companies, Inc. Stock Symbol: ICBU
  • The global race for next-gen precious metals recovery is accelerating: $AABB is positioning itself with it's Revolutionary rGO Gold Recovery System
  • Uk Financial Ltd Provides Investors Of Maya Preferred & Mayacat Instructions For Upcoming First Ever Listing Of Both Erc-3643 "SEC-Ready" Tokens
  • Dispelling Holiday Suicide Myth: CDC Data Shows Suicide Rates Lowest in December; International Survivors of Suicide Day Emphasizes Need for Action
  • Stratum Nutrition's OVOLUX™ Named 2025 "Collagen Ingredient of the Year" by Beauty Innovation Awards
  • Revenue Expansion, Regulatory Momentum, and a Leadership Position in the $750 Million Suicidal Depression: NRx Pharmaceuticals (N A S D A Q: NRXP)
  • Ali Alijanian, DDS Featured in The Profitable Dentist Magazine
  • CCHR: Study Finds Involuntary Commitment Fails to Prevent Suicide, Raises Risk
  • UV Weathering Test Chamber vs Xenon Arc Test Chamber: What's the Right Solution for Your Products
  • Emeritus Addresses Hospital Bed Shortages with Smart Storage Solutions
Copyright © The PennZone | Theme: OMag by LilyTurf Themes
  • Contribute
  • Privacy Policy
  • Terms of Service
  • Contact Us